RT Journal Article
SR Electronic
T1 Cholesterol Metabolism—Impacts on SARS-CoV-2 Infection Prognosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20068528
DO 10.1101/2020.04.16.20068528
A1 Peng, Yumeng
A1 Wan, Luming
A1 Fan, Chen
A1 Zhang, Pingping
A1 Wang, Xiaolin
A1 Sun, Jin
A1 Zhang, Yanhong
A1 Yan, Qiulin
A1 Gong, Jing
A1 Yang, Huan
A1 Yang, Xiaopan
A1 Li, Huilong
A1 Wang, Yufei
A1 Zong, Yulong
A1 Yin, Feng
A1 Yang, Xiaoli
A1 Zhong, Hui
A1 Cao, Yuan
A1 Wei, Congwen
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.04.16.20068528.abstract
AB In this study, we specifically addressed the connection between the SARS-CoV-2 virus with host cholesterol metabolism. Plasma lipid profile was measured in 861 COVID-19 patients classified as mild (n=215), moderate (n=364), severe (n=217) or critical (n=65) and 1108 age- and sex-matched healthy individuals. We showed that the levels of both TG and HDL-C were significantly lower in patients with severe disease than in patients with moderate or mild disease. After successful treatment, cholesterol metabolism was reestablished in patients with SARS-CoV-2 infection. The serum concentrations of TC and HDL-C can be used as indicators of disease severity and prognosis in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a single center based retrospective study, not a clinical trial.Funding StatementThis work is funded by the National Natural Science Foundation of China (No.81572620) and Shandong Provincial Natural Science Foundation of China (No.ZR2015HM003)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, or code generated or used during the study are available from the corresponding author by request.